These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38245513)

  • 1. Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia.
    Gurbatri CR; Radford GA; Vrbanac L; Im J; Thomas EM; Coker C; Taylor SR; Jang Y; Sivan A; Rhee K; Saleh AA; Chien T; Zandkarimi F; Lia I; Lannagan TRM; Wang T; Wright JA; Kobayashi H; Ng JQ; Lawrence M; Sammour T; Thomas M; Lewis M; Papanicolas L; Perry J; Fitzsimmons T; Kaazan P; Lim A; Stavropoulos AM; Gouskos DA; Marker J; Ostroff C; Rogers G; Arpaia N; Worthley DL; Woods SL; Danino T
    Nat Commun; 2024 Jan; 15(1):646. PubMed ID: 38245513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer detection and treatment with engineered probiotics.
    Gurbatri CR; Radford G; Vrbanac L; Coker C; Im JW; Taylor SR; Jang Y; Sivan A; Rhee K; Saleh AA; Chien T; Zandkarimi F; Lia I; Lannagan TR; Wang T; Wright JA; Thomas E; Kobayashi H; Ng JQ; Lawrence M; Sammour T; Thomas M; Lewis M; Papanicolas L; Perry J; Fitzsimmons T; Kaazan P; Lim A; Marker J; Ostroff C; Rogers G; Arpaia N; Worthley DL; Woods SL; Danino T
    bioRxiv; 2023 Apr; ():. PubMed ID: 37066243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
    Petersen AM; Mirsepasi H; Halkjær SI; Mortensen EM; Nordgaard-Lassen I; Krogfelt KA
    J Crohns Colitis; 2014 Nov; 8(11):1498-505. PubMed ID: 24972748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeting engineered probiotic Escherichia coli Nissle 1917 inhibits colorectal tumorigenesis and modulates gut microbiota homeostasis in mice.
    Tang H; Zhou T; Jin W; Zong S; Mamtimin T; Salama ES; Jeon BH; Liu P; Han H; Li X
    Life Sci; 2023 Jul; 324():121709. PubMed ID: 37100380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amelioration of cadmium- and mercury-induced liver and kidney damage in rats by genetically engineered probiotic Escherichia coli Nissle 1917 producing pyrroloquinoline quinone with oral supplementation of citric acid.
    Raghuvanshi R; Chaudhari A; Kumar GN
    Nutrition; 2016; 32(11-12):1285-94. PubMed ID: 27209211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo.
    Schultz M; Watzl S; Oelschlaeger TA; Rath HC; Göttl C; Lehn N; Schölmerich J; Linde HJ
    J Microbiol Methods; 2005 Jun; 61(3):389-98. PubMed ID: 15767015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers.
    Henker J; Laass M; Blokhin BM; Bolbot YK; Maydannik VG; Elze M; Wolff C; Schulze J
    Eur J Pediatr; 2007 Apr; 166(4):311-8. PubMed ID: 17287932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects resulting from oral administration of
    Souza ELS; Campos CLV; Reis DC; Cassali GD; Generoso SV; Cardoso VN; Azevedo V; Medeiros JD; Fernandes GR; Nicoli JR; Martins FS
    Benef Microbes; 2020 Dec; 11(8):779-790. PubMed ID: 33191778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering Probiotic E. coli Nissle 1917 for Release of Therapeutic Nanobodies.
    Gurbatri C; Danino T
    Methods Mol Biol; 2024; 2748():289-305. PubMed ID: 38070121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers.
    Joeres-Nguyen-Xuan TH; Boehm SK; Joeres L; Schulze J; Kruis W
    Inflamm Bowel Dis; 2010 Feb; 16(2):256-62. PubMed ID: 19637333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective and challenges of live bacterial therapeutics from a superhero
    Effendi SSW; Ng IS
    Crit Rev Microbiol; 2023 Sep; 49(5):611-627. PubMed ID: 35947523
    [No Abstract]   [Full Text] [Related]  

  • 12. Expanding the toolbox of probiotic Escherichia coli Nissle 1917 for synthetic biology.
    Ba F; Zhang Y; Ji X; Liu WQ; Ling S; Li J
    Biotechnol J; 2024 Jan; 19(1):e2300327. PubMed ID: 37800393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The beneficial effects of genetically engineered Escherichia coli Nissle 1917 in obese C57BL/6J mice.
    Ma J; Wang J; Xu L; Liu Y; Gu J
    Int J Obes (Lond); 2022 May; 46(5):1002-1008. PubMed ID: 35079130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a new T7 promoter compatible Escherichia coli Nissle 1917 strain for recombinant production of heme-dependent proteins.
    Fiege K; Frankenberg-Dinkel N
    Microb Cell Fact; 2020 Oct; 19(1):190. PubMed ID: 33023596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers.
    Henker J; Laass MW; Blokhin BM; Maydannik VG; Bolbot YK; Elze M; Wolff C; Schreiner A; Schulze J
    Pediatr Infect Dis J; 2008 Jun; 27(6):494-9. PubMed ID: 18469732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotic Escherichia coli Nissle 1917 reduces growth, Shiga toxin expression, release and thus cytotoxicity of enterohemorrhagic Escherichia coli.
    Mohsin M; Guenther S; Schierack P; Tedin K; Wieler LH
    Int J Med Microbiol; 2015 Jan; 305(1):20-6. PubMed ID: 25465158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Colonization and Therapy by
    Gentschev I; Petrov I; Ye M; Kafuri Cifuentes L; Toews R; Cecil A; Oelschaeger TA; Szalay AA
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy.
    Li R; Helbig L; Fu J; Bian X; Herrmann J; Baumann M; Stewart AF; Müller R; Li A; Zips D; Zhang Y
    Res Microbiol; 2019 Mar; 170(2):74-79. PubMed ID: 30447257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88.
    Remer KA; Bartrow M; Roeger B; Moll H; Sonnenborn U; Oelschlaeger TA
    Int J Med Microbiol; 2009 Nov; 299(7):467-78. PubMed ID: 19467927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of E. coli strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation.
    Hernando-Harder AC; von Bünau R; Nadarajah M; Singer MV; Harder H
    Dig Dis Sci; 2008 Feb; 53(2):443-50. PubMed ID: 17712634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.